## Koyamangalath Krishnan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5431045/publications.pdf

Version: 2024-02-01

58 papers 1,382 citations

430874 18 h-index 36 g-index

61 all docs

61 docs citations

times ranked

61

1816 citing authors

#	Article	IF	Citations
1	Burkitt lymphoma: interpreting FISH testing for MYC gene rearrangements. BMJ Case Reports, 2022, 15, e246687.	0.5	O
2	Covalent and Noncovalent Loading of Doxorubicin by Folic Acid-Carbon Dot Nanoparticles for Cancer Theranostics. ACS Omega, 2022, 7, 23322-23331.	3.5	10
3	Chronic mast cell leukaemia with exon 9 <i>KIT</i> mutation A502_Y503dup: a rare imatinib responsive variant. BMJ Case Reports, 2020, 13, e236447.	0.5	O
4	Upregulation of pERK and c-JUN by $\hat{i}^3$ -tocotrienol and not $\hat{i}$ ±-tocopherol are essential to the differential effect on apoptosis in prostate cancer cells. BMC Cancer, 2020, 20, 428.	2.6	14
5	Severe sunitinib-induced myelosuppression in a patient with a CYP 3A4 polymorphism. Journal of Oncology Pharmacy Practice, 2018, 24, 623-626.	0.9	6
6	$\hat{l}^3$ -Tocotrienol induces apoptosis in pancreatic cancer cells by upregulation of ceramide synthesis and modulation of sphingolipid transport. BMC Cancer, 2018, 18, 564.	2.6	19
7	PARANEOPLASTIC CEREBELLAR DEGENERATION (PCD) IN EXTENSIVE STAGE SCLC IN REMISSION. Chest, 2018, 154, 618A.	0.8	O
8	Severe bleeding with subclinical oculocutaneous albinism in a patient with a novel HPS6 missense variant. American Journal of Medical Genetics, Part A, 2018, 176, 2819-2823.	1.2	7
9	Successful Salvage with Inotuzumab Ozogamicin in Relapsed/Refractory Lymphoid Blast Crisis of Chronic Myeloid Leukemia after Failure of Multiple Lines of Therapy Including Blinatumomab. Blood, 2018, 132, 5452-5452.	1.4	3
10	Novel Hermanksky-Pudlak Syndrome Type 6 Missense Variant Associated with Subclinical Oculocutaneous Albinism and Mild Bleeding. Blood, 2018, 132, 1153-1153.	1.4	0
11	Breaking bad news to patients with cancer: A randomized control trial of a brief communication skills training module incorporating the stories and preferences of actual patients. Patient Education and Counseling, 2017, 100, 655-666.	2.2	64
12	A Systems Medicine Approach to the Role of Vitamins in Protecting the Gastrointestinal Tract From Oxidative Stress., 2017,, 217-227.		0
13	Synergistic growth inhibition of PC3 prostate cancer cells with low-dose combinations of simvastatin and alendronate. Anticancer Research, 2015, 35, 1851-9.	1.1	13
14	Tocotrienols in Pancreatic Cancer Treatment and Prevention., 2014,, 247-254.		0
15	The role of antioxidants and pro-oxidants in colon cancer. World Journal of Gastrointestinal Oncology, 2014, 6, 55.	2.0	60
16	A â€~double-hit' bone marrow rare co-occurrence of 2 different pathologies. Journal of Community and Supportive Oncology, 2014, 12, 33-34.	0.1	2
17	A Summary of the Prostate Cancer Prevention Trials With a Focus on the Role of Vitamin E. Home Health Care Management and Practice, 2013, 25, 23-28.	1.0	2
18	Successful treatment of nilotinib-induced pleural effusion with prednisone. Journal of Oncology Pharmacy Practice, 2013, 19, 175-177.	0.9	10

#	Article	IF	Citations
19	Gamma-Tocotrienol and Simvastatin Synergistically Induce Cytotoxicity In Leukemia Cell Lines, K-562 and HL-60. Blood, 2013, 122, 4927-4927.	1.4	1
20	Anti-Neoplastic Activity of Two Flavone Isomers Derived from Gnaphalium elegans and Achyrocline bogotensis. PLoS ONE, 2012, 7, e39806.	2.5	22
21	A Rare Case of Paradoxical Renal Embolus Through Patent Foramen Ovale. Chest, 2012, 142, 346A.	0.8	O
22	A specific molecular beacon probe for the detection of human prostate cancer cells. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3632-3638.	2.2	6
23	Understanding the Role of Religion in Cancer Care in Appalachia. Southern Medical Journal, 2011, 104, 295-296.	0.7	14
24	Differential Effects of Pravastatin and Simvastatin on the Growth of Tumor Cells from Different Organ Sites. PLoS ONE, 2011, 6, e28813.	2.5	71
25	$\hat{I}^3$ -Tocotrienol induces growth arrest through a novel pathway with TGF $\hat{I}^2$ 2 in prostate cancer. Free Radical Biology and Medicine, 2011, 50, 1344-1354.	2.9	44
26	Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway. Free Radical Biology and Medicine, 2011, 51, 1164-1174.	2.9	89
27	Polyphenon E Inhibits the Growth of Human Barrett's and Aerodigestive Adenocarcinoma Cells by Suppressing Cyclin D1 Expression. Clinical Cancer Research, 2009, 15, 622-631.	7.0	18
28	Gamma Tocopherol Upregulates the Expression of 15-S-HETE and Induces Growth Arrest Through a PPAR Gamma-Dependent Mechanism in PC-3 Human Prostate Cancer Cells. Nutrition and Cancer, 2009, 61, 649-662.	2.0	39
29	Î <sup>3</sup> -Tocotrienol Inhibits Nuclear Factor-κB Signaling Pathway through Inhibition of Receptor-interacting Protein and TAK1 Leading to Suppression of Antiapoptotic Gene Products and Potentiation of Apoptosis. Journal of Biological Chemistry, 2007, 282, 809-820.	3.4	230
30	Understanding the Challenges of Reducing Cancer in Appalachia. Californian Journal of Health Promotion, 2007, 5, 40-49.	0.3	34
31	Vitamin E Isoforms Inhibit Cell Proliferation and Downregulate Homeobox Protein Expression in the Leukemic KG-1 Cells Blood, 2007, 110, 4304-4304.	1.4	O
32	More optimal forms of vitamin E. Journal of the American Dietetic Association, 2005, 105, 204-205.	1.1	2
33	Effects of low dose aspirin (81 mg) on proliferating cell nuclear antigen and Amaranthus caudatus labeling in normal-risk and high-risk human subjects for colorectal cancer. Cancer Detection and Prevention, 2004, 28, 107-113.	2.1	3
34	Tocopherols and the Treatment of Colon Cancer. Annals of the New York Academy of Sciences, 2004, 1031, 223-233.	3.8	69
35	Preferential Uptake of Gamma Tocopherol by Mast Cells. Does This Uptake Affect Mast Cell Cytokine Production? Blood, 2004, 104, 3793-3793.	1.4	O
36	Serologically documented loracarbef (Lorabid)-induced immune thrombocytopenia. American Journal of Hematology, 2003, 73, 41-43.	4.1	12

#	Article	IF	CITATIONS
37	Development of gamma ( $\hat{I}^3$ )-tocopherol as a colorectal cancer chemopreventive agent. Critical Reviews in Oncology/Hematology, 2003, 47, 249-259.	4.4	81
38	Septic Discitis: An Important Cause of Back Pain. Southern Medical Journal, 2003, 96, 692-695.	0.7	17
39	Cancer Chemoprevention Drug Targets. Current Drug Targets, 2003, 4, 45-54.	2.1	36
40	THE RISE AND FALL OF HORMONE REPLACEMENT THERAPY: ONCOLOGISTS' VIEWS. Southern Medical Journal, 2002, 95, 963-965.	0.7	2
41	PROSTAGLANDIN INHIBITORS AND THE CHEMOPREVENTION OF NONCOLONIC MALIGNANCY. Gastroenterology Clinics of North America, 2001, 30, 981-1000.	2.2	13
42	Reactive and clonal thrombocytosis: proinflammatory and hematopoietic cytokines and acute phase proteins. Southern Medical Journal, 2001, 94, 417-20.	0.7	7
43	Chemoprevention for colorectal cancer. Critical Reviews in Oncology/Hematology, 2000, 33, 199-219.	4.4	27
44	Right Atrial Myxoma With Extracardiac Manifestations. Chest, 2000, 118, 547-549.	0.8	23
45	Severe bactrim-induced neutropenia with reversal of CD4+ /CD8+ lymphocyte ratio: response to recombinant human granulocyte-colony stimulating factor (R-metHUG-CSF). International Journal of Laboratory Hematology, 1998, 20, 187-188.	0.2	1
46	CANCER CHEMOPREVENTION. Primary Care - Clinics in Office Practice, 1998, 25, 361-379.	1.6	12
47	CLINICAL MODELS OF CHEMOPREVENTION FOR COLON CANCER. Hematology/Oncology Clinics of North America, 1998, 12, 1079-1113.	2.2	10
48	Isolated Pancreatic Extramedullary Hematopoiesis. Acta Haematologica, 1998, 99, 38-40.	1.4	11
49	Suppression of Human Colorectal Mucosal Prostaglandins: Determining the Lowest Effective Aspirin Dose. Journal of the National Cancer Institute, 1997, 89, 1152-1160.	6.3	113
50	Successful treatment of autoimmune neutropenia with recombinant human granulocyte-colony stimulating factor (R-metHuG-CSF). International Journal of Laboratory Hematology, 1997, 19, 105-109.	0.2	12
51	Colon cancer chemoprevention: Clinical development of aspirin as a chemopreventive agent. Journal of Cellular Biochemistry, 1997, 67, 148-158.	2.6	14
52	Familial Association of Primary Pulmonary Hypertension and a New Low-Oxygen Affinity $\hat{l}^2$ -Chain Hemoglobinopathy, Hb Washtenaw. Chest, 1996, 109, 848-850.	0.8	13
53	Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self-report and microelectronic monitoring. Archives of Family Medicine, 1996, 5, 297-300.	1.2	57
54	Bilateral orbital tumors and lacrimal gland involvement in Waldenstr $ ilde{A}\P$ m's macroglobulinemia. European Journal of Haematology, 1995, 55, 205-206.	2,2	12

#	Article	IF	CITATIONS
55	Myasthenia gravis following iron chelation therapy with intravenous desferrioxamine. European Journal of Haematology, 1995, 55, 138-139.	2.2	3
56	Neural cell-adhesion molecule (CD 56)-positive, t(8; 21) acute myeloid leukemia (AML, M-2) and granulocytic sarcoma. Annals of Hematology, 1994, 69, 321-323.	1.8	36
57	HB Washtenaw [βT11(A8)VAL-PHE]: An Electrophoretically Silent, Unstable, Low Oxygen Affinity Variant Associated with Anemia and Chronic Cyanosis. Hemoglobin, 1994, 18, 285-295.	0.8	17
58	Paraneoplastic cutaneous leucocytoclastic vasculitis in chronic myeloid leukemia: case report and review of the literature. European Journal of Haematology, 1994, 52, 187-8.	2.2	1